EZH2 Inhibitors Promote β-Like Cell Regeneration in Young and Adult Type 1 Diabetes Donors

The authors showed that transient stimulation of exocrine cells, derived from juvenile and adult type 1 diabetes donors to the FDA-approved EZH2 inhibitors GSK126 and Tazemetostat influenced a phenotypic shift towards a β-like cell identity.